227 related articles for article (PubMed ID: 2585020)
1. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
6. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
9. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone.
Jacob MC; Piccinni MP; Bonnefoix T; Sotto MF; Couderc P; Bensa JC; Sotto JJ
Blood; 1990 Mar; 75(5):1154-62. PubMed ID: 2306520
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology.
Schuurman HJ; van Baarlen J; Huppes W; Lam BW; Verdonck LF; van Unnik JA
Am J Pathol; 1987 Oct; 129(1):140-51. PubMed ID: 3310650
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma--an experience from a medical center in Southern Taiwan.
Hsieh CI; Su WC; Chien CH; Cuo YL; Chen TY; Kao RH; Tsao CJ
Kaohsiung J Med Sci; 1996 Feb; 12(2):69-82. PubMed ID: 8709176
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
13. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
14. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.
Schuurman HJ; Huppes W; Verdonck LF; Van Baarlen J; Van Unnik JA
Am J Pathol; 1988 Apr; 131(1):102-11. PubMed ID: 3258475
[TBL] [Abstract][Full Text] [Related]
16. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.
Salter DM; Krajewski AS; Sheehan T; Turner G; Cuthbert RJ; Mclean A
J Pathol; 1989 Nov; 159(3):211-20. PubMed ID: 2593045
[TBL] [Abstract][Full Text] [Related]
18. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
20. CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
Jacob MC; Favre M; Lemarc'Hadour F; Sotto MF; Bonnefoix T; Sotto JJ; Bensa JC
Am J Hematol; 1992 Jan; 39(1):45-51. PubMed ID: 1531569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
